MarketMoodz
Moleculin Nears First MIRACLE Data Unblinding Before June
Moleculin Biotech (MBRX) is on track to unblind the first set of data from its MIRACLE Phase 2B/3 trial before June 30, 2026, a near-term event that could act as a catalyst for the nano-cap biotech. The adaptive, randomized, double-blind study tests Annamycin at 190 mg/m² and 230 mg/m² with cytarabine in relapsed or refractory AML and allows interim unblinding after the first 45 patients and again after all 90 Part A patients are enrolled.
Key Takeaways
- Moleculin expects to unblind the first MIRACLE data before June 30, 2026, under the trial's interim rules.
- Part A randomizes two Annamycin doses (190 mg/m² and 230 mg/m²) plus cytarabine against cytarabine with placebo.
- The design permits preliminary unblinding after 45 patients and a second read after all 90 Part A patients are enrolled.
- As of May 1, 2026, 56 patients were enrolled; Moleculin projects Part A will reach 90 patients in Q3 2026.
- Preliminary blinded data from 45 subjects showed a composite complete remission rate >40% and a CR rate ~30% versus historical cytarabine CRs of ~17%–18%, though those figures are early and unverified.
People Involved
- Walter KlempChief Executive Officer, Moleculin Biotech
Entities Involved
- Moleculin Biotech Inc. (MBRX)Sponsor and developer of Annamycin; sponsor of the MIRACLE trial
- AnnamycinInvestigational anthracycline partnered with cytarabine in MIRACLE
- CytarabineStandard chemotherapy backbone used in the control arm
- MIRACLE trialGlobal, randomized, double-blind, placebo-controlled adaptive Phase 2B/3 study
MarketMoodz Analysis
For investors, the first MIRACLE unblinding is a classic binary catalyst for a small-cap oncology stock. A positive interim read that shows materially higher remission rates than historical cytarabine benchmarks could lift MBRX by improving commercialization, partnering, or licensing prospects; conversely, inconclusive or disappointing data would likely pressure the share price given the company's dependence on this single program. The market will focus on both efficacy signals and safety outcomes, and volatility should be expected around any press release or presentation.
Context matters: the trial’s adaptive design allows early looks after 45 patients, but small sample sizes and cross-trial comparisons to historical cytarabine rates (roughly 17%–18%) carry large statistical uncertainty. The reported preliminary blinded composite CR >40% and CR ~30% are encouraging if confirmed, but those early figures are unverified and subject to selection bias and differing patient mixes—median age in the mid-60s and more than 30% with prior venetoclax-based frontline therapy could skew outcomes versus older datasets. Investors should treat interim results as directional, not definitive.
What to watch next: confirmatory details at the unblinding (number of evaluable patients, response definitions, duration of remission, and safety signals), the timing of the second Part A read after enrollment reaches 90, and any guidance on enrollment pace—Moleculin reported 56 enrolled as of May 1, 2026 and projects finishing Part A in Q3 2026. Also monitor trading volume and analyst commentary; MBRX traded down about 5.13% to $2.22 at publication, with a year-to-date decline near 32.9% and a trailing-month drop around 18.3%, underscoring how sensitive the stock is to data flow.
Source: Original Article